Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$69.06−5.12 (-6.90%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield –
Inhibrx Biosciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Inhibrx Biosciences's price to sales ratio was 348.3× on Sep 30, 2025, against 334.4× a year earlier. Over the last 4 years it ranged from 13.6× to 390.0×, with a median of 50.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Sep 30, 2025 | 348.3× | +219.7 |
| 2024 | Dec 31, 2024 | 128.6× | −153.4 |
| 2023 | Oct 31, 2023 | 281.9× | +231.5 |
| 2022 | Dec 30, 2022 | 50.4× | −7.5 |
| 2021 | Dec 31, 2021 | 57.9× | +28.0 |
| 2020 | Dec 31, 2020 | 30.0× | – |
See a number that looks wrong?